Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

University of Texas Southwestern Medical Center · with American Heart Association · NCT06814587

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 20–80 · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
15
US sites recruiting
1
Study start
July 1, 2024
Record last updated
September 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and Hyperpolarized Carbon-13 (HP-13C) Pyruvate Magnetic Resonance Imaging (MRI). Under this protocol, the SPECT MPI and FDG-PET exams will be used in combination to comprehensively assess myocardial viability. Concurrently, the HP-13C Pyruvate MRI will be utilized to provide additional insights into myocardial metabolism. The study will evaluate healthy volunteers to establish baseline parameters and patients with ischemic cardiomyopathy (ICM) before and after surgical revascularization.

Being studied: Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI); [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET); SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)

Conditions: Coronary Artery Disease; Coronary Artery Bypass Graft (CABG)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Study Population Description The study population will consist of 12 to 15 human subjects divided into two main groups. The first group includes 6 healthy individuals with a normal left ventricular ejection fraction (LVEF > 0.50). The second group comprises 9 patients with advanced ischemic cardiomyopathy (ICM) and a low LVEF (\< 0.40) who are scheduled for standard-of-care Coronary Artery Bypass Graft (CABG) surgery. The study team will aim to recruit a mixed-sex, age-matched population with equal numbers for all metabolic imaging studies.

Ischemic Cardiomyopathy (ICM) Patient Cohort

Inclusion Criteria

Male or Female, age 18-80 years. Patient scheduled for Coronary Artery Bypass Surgery as standard of care therapy per clinical guidelines.

Presence of 1 or more stenotic coronary artery vessels. Left Ventricular Ejection Fraction (LVEF) ≤ 40%, or clinical indication for myocardial viability assessment.

Able to tolerate FDG PET/MRI protocol and preparation (e.g., fasting state, glucose regulation).

Medication use within 24 hours of the scan is allowed and will be reported. Negative pregnancy test for females of childbearing age (on the day of scanning).

No known contraindications to 3T MRI, SPECT MPI, or FDG PET.

Exclusion Criteria

Male or female, age \< 18 or > 80 years of age. Patients not scheduled for CABG or those without confirmed coronary artery disease (CAD).

History of prior myocardial infarction with transmural scar > 50% (based on prior imaging or clinical history).

Patient not eligible for 3T MRI (Any condition or device precluding safe MRI e.g., pacemakers, defibrillators, metal implants), SPECT (significant arrhythmias or hemodynamic instability), or FDG-PET (e.g., severely impaired glucose metabolism).

Positive pregnancy test or females currently breastfeeding (on the day of scanning).

Severe renal impairment (GFR \< 30 mL/min) or contraindication to FDG PET tracer.

History of uncontrolled diabetes mellitus (HbA1c > 9%) or inability to achieve stable glucose levels for FDG PET preparation.

Healthy Volunteer Cohort

Inclusion Criteria

Male or Female, age 18-80 years. No history of coronary artery disease or diabetes. Eligible for 3T MRI, SPECT, and FDG-PET. Negative pregnancy test for females of childbearing age (on the day of scanning).

Exclusion Criteria

History of coronary artery disease, diabetes, or other medical conditions deemed exclusionary by the study team.

Positive pregnancy test or females currently breastfeeding (on the day of scanning).

Contraindications to MRI (e.g., metallic implants, claustrophobia), SPECT MPI, or FDG-PET.

Recruiting US locations

  • University of Texas Southwestern Medical Center

    Dallas, TX 75390

    Site contact: Sarah McNeil · 214-645-7700 · sarah.mcneil@utsouthwestern.edu

Study contacts (from the official record)

  • Sarah McNeil, RN · 214-645-7700 · sarah.mcneil@utsouthwestern.edu
  • Cesia Rodriguez Gongora, RN · 214/645-7739 · cesia.rodriguezgongora@utsouthwestern.edu
Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for… (NCT06814587) | Bored Studies